SCHEMBL504510

SCHEMBL504510

N#Cc1cccc(-c2nc3c(o2)CNCC3)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 6/20 0.44
NOTUM Q6P988 1/20 0.44
MAOB P27338 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA5 P30532 1/20 0.41
CHRNA4 P43681 1/20 0.41
GPR119 Q8TDV5 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
ATR Q13535 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
PNMT P11086 1/20 0.38
IDO1 P14902 2/20 0.38
PGR P06401 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
XDH P47989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504615 0.90 NOTUM (0.44) GRM5NOTUMMAOBCHRNB2CHRNA5
SCHEMBL505537 0.90 NOTUM (0.46) GRM5NOTUMMAOBCHRNB2CHRNA5
SCHEMBL2590357 0.82 CYP3A4 (0.47) GPR119NPC1HPGDRAB9A
SCHEMBL505104 0.82 NPC1 (0.52) NOTUMNPC1ALDH1A1HPGDRAB9A
Hydrochloric Acid SCHEMBL504535 0.81 CYP3A4 (0.46) GPR119NPC1HPGDRAB9A
SCHEMBL504758 0.79 RAB9A (0.55) NOTUMMAOBNPC1ALDH1A1HPGD
SCHEMBL504865 0.76 GRM5 (0.74) GRM5NOTUMGPR119DRD2DRD3
SCHEMBL505191 0.75 GPR119 (0.42) GRM5NOTUMCHRNB2CHRNA5CHRNA4
SCHEMBL504599 0.75 PKN2 (0.41) CHRNB2CHRNA4GPR119NPC1HPGD
SCHEMBL17984261 0.75 HDAC6 (0.36) NOTUMCHRNB2CHRNA5CHRNA4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414340-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120029190-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2012-02-02 US disclosed
WO-2010114971-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029190-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF GRM5, GRM2, GRM1 GRM5 1/4885NOTUM 3205/4885MAOB 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.